November 2014 – The CenterWatch Monthly : Print
Private equity fueling CRO growth, expansion
Private equity, which has been very active in the CRO space over the past five years, is reshaping the CRO landscape—giving the industry financial stability it might not otherwise have and providing the capital for CROs to expand, both organically and inorganically, to offer a broader range of services and greater efficiency to support R&D innovation.
Baby Boomers poised to reshape clinical trials industry
Look out, clinical research: Here come the baby boomers, that over-analyzed, massive cohort of Americans born between 1946 and 1964. They’re large (75 million strong), they’re aging (each year, about 3 million will hit retirement age through 2029) and they’re the most ethnically and racially diverse, well-off and well-educated generation yet.
Also in this issue:
- Challenging traditional data review models
- Strategies for accelerated study startup
- Regulatory Update
- Month in Review
- Study Lead Opportunities
- FDA Actions
- New Drugs in the Pipeline